Nektar Therapeutics (NKTR) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Nektar Therapeutics faces a significant business risk after receiving a notice from Nasdaq regarding non-compliance with the Minimum Bid Price Rule. The company’s common stock failed to maintain the required $1.00 minimum closing bid price, prompting a potential delisting. Although Nektar Therapeutics has been granted an extension until May 20, 2024, to meet the criteria, which may involve a reverse stock split, there is no certainty of success. If compliance is not achieved and delisting occurs, it could detrimentally impact the stock’s marketability and the company’s capital-raising capabilities.
The average NKTR stock price target is $1.00, implying 9.90% upside potential.
To learn more about Nektar Therapeutics’ risk factors, click here.
